Tevogen Bio Holdings Inc. has announced its plans to expand its operations by leasing a 17,428-square-foot facility in New Jersey, previously occupied by Pfizer and Cordis. This state-of-the-art facility will be dedicated to GMP cell therapy manufacturing, aligning with Tevogen's strategic objectives to accelerate clinical development while ensuring cost efficiency and scalability. The move is set to support the company's growing pipeline, powered by its proprietary AI-driven target discovery platform, PredicTcell™. Tevogen anticipates beginning occupancy after finalizing the lease and obtaining necessary approvals, with the lease term expected to exceed five years. Dr. Ryan Saadi, CEO of Tevogen Bio, stated that this investment in infrastructure underscores the company's commitment to delivering innovative T cell therapies and efficiently scaling manufacturing as they move toward commercialization.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.